CCM
GNMK

Cadian Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Cadian Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,489,055
Closed -$14.4M – 29
2020
Q1 		$14.4M Sell
3,489,055
-2,028,712
-37% -$9.51M 0.71% 21
2019
Q4 		$26.5M Sell
5,517,767
-125,351
-2% -$691K 1.17% 23
2019
Q3 		$34.2M Buy
5,643,118
+2,370
+0% +$14.8K 1.63% 18
2019
Q2 		$36.6M Buy
5,640,748
+488,739
+9% +$3.44M 1.65% 20
2019
Q1 		$36.5M Buy
5,152,009
+143,887
+3% +$948K 1.43% 19
2018
Q4 		$24.3M Buy
5,008,122
+1,177,723
+31% +$6.13M 1.13% 22
2018
Q3 		$28.2M Sell
3,830,399
-649,216
-14% -$4.76M 1.28% 23
2018
Q2 		$28.6M Sell
4,479,615
-561,518
-11% -$3.71M 1.38% 21
2018
Q1 		$27.4M Buy
5,041,133
+23,650
+0.5% +$118K 1.48% 17
2017
Q4 		$20.9M Buy
5,017,483
+985,000
+24% +$5.93M 1.27% 19
2017
Q3 		$38.8M Buy
4,032,483
+47,123
+1% +$490K 1.82% 18
2017
Q2 		$47.1M Buy
3,985,360
+798,978
+25% +$10.2M 2.3% 16
2017
Q1 		$40.8M Sell
3,186,382
-73,996
-2% -$891K 1.95% 19
2016
Q4 		$39.9M Sell
3,260,378
-321,369
-9% -$3.82M 2.12% 16
2016
Q3 		$42.3M Sell
3,581,747
-499,012
-12% -$4.82M 2.23% 15
2016
Q2 		$35.5M Buy
4,080,759
+240,000
+6% +$1.65M 1.95% 19
2016
Q1 		$20.2M Buy
3,840,759
+75,600
+2% +$421K 1.36% 22
2015
Q4 		$29.2M Buy
3,765,159
+1,104,964
+42% +$8.49M 1.05% 26
2015
Q3 		$20.9M Buy
2,660,195
+1,238,733
+87% +$11.5M 0.75% 41
2015
Q2 		$12.9M Buy
1,421,462
+483,962
+52% +$4.88M 0.38% 52
2015
Q1 		$12.2M Hold
937,500
– – 0.33% 52
2014
Q4 		$12.8M Buy
937,500
+50,000
+6% +$559K 0.32% 57
2014
Q3 		$7.96M Hold
887,500
– – 0.21% 59
2014
Q2 		$12M Buy
887,500
+12,500
+1% +$130K 0.36% 55
2014
Q1 		$8.7M Buy
875,000
+100,000
+13% +$1.24M 0.22% 59
2013
Q4 		$10.3M Buy
775,000
+320,000
+70% +$3.89M 0.27% 60
2013
Q3 		$5.52M Buy
+455,000
New +$4.88M 0.16% 63

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cadian Capital Management's GNMK Position: Q2 2020 in Review

Cadian Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 3,489,055 shares — an estimated $14.4M sold.

Cadian Capital Management first reported a position in GNMK in Q3 2013 and held it in 27 quarters. The position peaked at $47.1M in Q2 2017. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

  • Cadian Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
  • Cadian Capital Management sold 3,489,055 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $14.4M.
  • Cadian Capital Management first reported a position in GenMark Diagnostics, Inc in Q3 2013 and held it in 27 quarters.
  • Cadian Capital Management's GenMark Diagnostics, Inc position peaked at $47.1M in Q2 2017.
  • 148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Cadian Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.